jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The jCell dose being studied in this trial is approximately 50% higher than the highest dose administered in previous jCyte clinical trials. Retinitis pigmentosa is a rare genetic disorder that leads to progressive loss of the rod and cone photore
Related Questions
How might the initiation of the JC02-88 trial and the higher cell dose affect JCyte's short‑term stock volatility and valuation multiples?
What is the expected timeline for data readout from this trial, and how could that timeline align with upcoming FDA interactions or potential partnership announcements?
How does jCell’s mechanism and dosing strategy compare with other gene‑ or cell‑based therapies targeting retinitis pigmentosa in terms of efficacy, safety, and market size?